Geoffrey Clark Lab

Sidebar

About 

Ras is arguably the most important oncogene of all.  Mutations in RAS may drive a third of human cancers.  Moreover, many cancers that lack mutations in RAS itself are often still driven by RAS due to dysfunction of the proteins that normally regulate RAS. Until recently, there were no targeted therapies that were effective against the RAS protein.   We have developed a series of small molecules targeting directly and indirectly various key components of RAS mediated oncogenic transformation.  We are testing them against a variety of RAS driven cancer models.  These include well established RAS driven cancers such as pancreatic and lung, as well as several cancers not typically associated with RAS, such as breast, ovarian and pediatric High grade glioblastoma. 

Key Research Areas

  • Ras Oncogene
  • RASSF tumor suppressor
  • Targeted therapy
  • Drug development

Current Projects

  • Development of novel RAS inhibitors
  • Development and characterization of RALGEF inhibitors
  • Development of IL-6 inhibitors
  • Development of PD-1 inhibitors
  • Role of NORE1A/RASSF5 in liver disease

Team 

  • Rachel Ferrill, BS, Masters student.
  • Becca Baby, technician,
  • Sarah Wilcher, technician
  • Raphael Jigo, BS, PhD student.

Recent Publications

Geoffrey Clark Lab

Department of Pharmacology and Toxicology

Website about

Phone

502–852–4485

Location

Clinical Translational Research Building, 505 S Hancock St., Room 417

Email